These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34625389)

  • 21. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
    Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
    Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Boyle MG; Bajorin DF
    Cancer; 2007 Feb; 109(3):549-55. PubMed ID: 17200962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
    Strouse JJ; Spevak M; Mack AK; Arceci RJ; Small D; Loeb DM
    Pediatr Blood Cancer; 2005 Apr; 44(4):407-11. PubMed ID: 15602719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
    Walsh A; Kelly DR; Vaid YN; Hilliard LM; Friedman GK
    Pediatr Blood Cancer; 2010 Dec; 55(6):1217-20. PubMed ID: 20979179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
    Waters JS; Moss C; Pyle L; James M; Hackett S; A'hern R; Gore M; Eisen T
    Br J Cancer; 2004 Nov; 91(10):1763-8. PubMed ID: 15505625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
    Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
    Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
    Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
    Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
    Ricci S; Galli L; Chioni A; Iannopollo M; Antonuzzo A; Francesca F; Vocaturo V; Selli C; Orlandini C; Conte P
    Cancer; 2002 Oct; 95(7):1444-50. PubMed ID: 12237912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.
    Wiele AJ; Surasi DS; Rao P; Sircar K; Su X; Bathala TK; Shah AY; Jonasch E; Cataldo VD; Genovese G; Karam JA; Wood CG; Tannir NM; Msaouel P
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
    Oudard S; Banu E; Vieillefond A; Fournier L; Priou F; Medioni J; Banu A; Duclos B; Rolland F; Escudier B; Arakelyan N; Culine S;
    J Urol; 2007 May; 177(5):1698-702. PubMed ID: 17437788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
    Lim KH; Kim TY; Lee KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1017-26. PubMed ID: 21327930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
    Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D
    Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy.
    Wang YS; Tian J; Han Y; Han SM; Shi SB
    Oncol Res; 2016; 24(2):129-35. PubMed ID: 27296953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
    Porta C; Zimatore M; Imarisio I; Natalizi A; Sartore-Bianchi A; Danova M; Riccardi A
    Cancer; 2004 May; 100(10):2132-8. PubMed ID: 15139055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.